Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XOMA 052 (Gevokizumab) in Well-Controlled Type 1 Diabetes
NCT01788033Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Sep 2009
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing XOMA 052 with Placebo (2 arms). Primary endpoint: C-peptide level (incremental AUC over 120 minutes during MMTT) at Day 112. Started Sep 2009; status: completed.
02
Drugs
gevokizumab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01788033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01788033.